51
|
Motzer RJ, Alyasova A, Ye D, Karpenko A, Li H, Alekseev B, Xie L, Kurteva G, Kowalyszyn R, Karyakin O, Neron Y, Cosgriff T, Collins L, Brechenmacher T, Lin C, Morgan L, Yang L. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 2015; 27:441-8. [PMID: 26681676 DOI: 10.1093/annonc/mdv612] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Accepted: 12/05/2015] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND RECORD-1 demonstrated clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) previously treated with sunitinib, sorafenib, or both; prior treatment with cytokines, bevacizumab, and chemotherapy was also permitted. RECORD-4 prospectively assessed everolimus in a purely second-line setting. METHODS Patients with clear-cell mRCC were enrolled into one of three cohorts based on first-line therapy with sunitinib, other anti-VEGF agents, or cytokines. Patients were treated with everolimus 10 mg/day until progression (RECIST, v1.0) or intolerance. The primary end point was progression-free survival (PFS) per investigator review. Data cutoff was 1 September 2014, for the primary analysis and 26 June 2015, for the final overall survival (OS) analysis. RESULTS Enrolled patients (N = 134) previously received sunitinib (n = 58), other anti-VEGF therapy (n = 62; sorafenib, 23; bevacizumab, 16; pazopanib, 13; tivozanib, 5; and axitinib, 3), or cytokines (n = 14). Overall median age was 59 years, and most patients were men (68%) and of favorable/intermediate MSKCC risk (52/37%). Overall median PFS was 7.8 months [95% confidence interval (CI) 5.7-11.0]; in the cohorts, it was 5.7 months (95% CI 3.7-11.3) with previous sunitinib, 7.8 months (95% CI 5.7-11.0) with other previous anti-VEGF therapy, and 12.9 months [95% CI 2.6-not estimable (NE)] with previous cytokines. Overall, 67% of patients achieved stable disease as their best objective response. At final OS analysis, total median OS was 23.8 months (95% CI 17.0-NE) and, in the cohorts, it was 23.8 months (95% CI 13.7-NE) with previous sunitinib, 17.2 months (95% CI 11.9-NE) with other previous anti-VEGF therapy, and NE (95% CI 15.9-NE) with previous cytokine-based therapy. Overall, 56% of patients experienced grade 3 or 4 adverse events (regardless of relationship to study drug). CONCLUSIONS These results confirm the PFS benefit of second-line everolimus after first-line sunitinib or other anti-VEGF therapies. The safety profile of everolimus was consistent with previous experience. CLINICAL TRIAL NAME AND IDENTIFIER Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD-4), ClinicalTrials.gov identifier, NCT01491672.
Collapse
|
52
|
Uemura H, Ye D, Wu TL, Lee JY, Chong Y, Razack A, Pripatnanont C, Chiong E, Lau W, Kanesvaran R, Li C, Rawal S, Tongaonkar H, Pu YS, Santingamkun A, Lojanapiwat B, Liang H, Mah K, van Kooten Losio M, Liu Y. 266TiP A multicenter, prospective, longitudinal registry of prostate cancer in Asia. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv524.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Yang L, Alyasova A, Ye D, Karpenko A, Li H, Alekseev B, Xie L, Kurteva G, Kowalyszyn R, Karyakin O, Nerón Y, Cosgriff T, Collins L, Brechenmacher T, Lin J, Morgan L, Motzer R. 239O RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv524.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
54
|
Alekseev B, Yang L, Alyasova A, Ye D, Karpenko A, Li H, Xie L, Kurteva G, Kowalyszyn R, Karyakin O, Neron Y, Cosgriff T, Collins L, Brechenmacher T, Lin J, Morgan L, Motzer R. 2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31438-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
55
|
Gu C, Li Q, Zhu Y, Qu Y, Zhang G, Wang M, Yang Y, Wang J, Jin L, Wei Q, Ye D. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. Prostate Cancer Prostatic Dis 2015; 18:310-6. [DOI: 10.1038/pcan.2015.27] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 04/08/2015] [Accepted: 04/13/2015] [Indexed: 02/06/2023]
|
56
|
Gomez-Hurtado N, Kryshtal D, Hwang H, Johnson C, Chazin W, Boczek N, Tester D, Ye D, Will M, Ackerman M, Knollmann B. CALMODULIN MUTATION (CALM1-E141G) ASSOCIATED WITH LONG QT SYNDROME DISRUPTS CALMODULIN CALCIUM BINDING AND IMPAIRS L-TYPE CA CHANNEL INACTIVATION. Heart Rhythm 2014. [DOI: 10.1016/j.hrthm.2014.09.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
57
|
Zhang W, Zhu C, Wu Y, Ye D, Wang S, Zou D, Zhang X, Kaplan DL, Jiang X. VEGF and BMP-2 promote bone regeneration by facilitating bone marrow stem cell homing and differentiation. Eur Cell Mater 2014; 27:1-11; discussion 11-2. [PMID: 24425156 DOI: 10.22203/ecm.v027a01] [Citation(s) in RCA: 120] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2) have been widely used in the fields of tissue engineering and regenerative medicine to stimulate angiogenesis and bone formation. The goal of this study was to determine whether VEGF and BMP-2 are involved in the homing of bone marrow stem cells (BMSCs) for bone regeneration and to provide insights into their mechanism of action. The chemoattraction of BMSCs to VEGF and BMP-2 was analysed in vitro using a checkerboard assay. VEGF and BMP-2 stimulated the chemotaxis of BMSCs but not chemokinesis. In vivo, both VEGF and BMP-2 also have been confirmed to induce the homing of tail vein injected BMSCs to the site of silk scaffold subcutaneous implantation in nude mice. When the scaffolds were implanted in the rabbit skull defects, more SSEA+ mesenchymal stem cells were mobilised and homed to silk scaffolds containing VEGF and/or BMP-2. More importantly, autogenic BMSCs were reinjected via the ear vein after labelling with lenti-GFP, and the cells were detected to home to the defects and differentiate into endothelial cells and osteogenic cells induced by VEGF and BMP-2. Finally, perfusion with Microfil showed that initial angiogenesis was enhanced in tissue-engineered complexes containing VEGF. Observations based on µCT assay and histological study revealed that bone formation was accelerated on BMP-2-containing scaffolds. These findings support our hypothesis that the localised release of VEGF and BMP-2 promote bone regeneration, in part by facilitating the mobilisation of endogenous stem cells and directing the differentiation of these cells into endothelial and osteogenic lineages.
Collapse
|
58
|
Traore H, Meda N, Nagot N, Somé E, Neboua D, Kankasa C, Hofmeyr J, Tumwine J, Vallo R, Ye D, Tylleskar T, Van de Perre P. Déterminants du faible poids de naissance chez des enfants nés de mères séropositives pour le VIH, non éligibles au traitement antirétroviral, en Afrique. Rev Epidemiol Sante Publique 2013; 61:413-20. [DOI: 10.1016/j.respe.2013.05.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Revised: 04/11/2013] [Accepted: 05/03/2013] [Indexed: 10/26/2022] Open
|
59
|
Lin F, Yu X, Zhang X, Guo Y, Huang Y, Zhou J, Zeng P, Ye D, Huang Y. A synthetic analog of lipoxin A4 partially alleviates dexamethasone-induced fetal growth restriction in rats. Placenta 2013; 34:941-8. [DOI: 10.1016/j.placenta.2013.07.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2012] [Revised: 07/11/2013] [Accepted: 07/15/2013] [Indexed: 12/20/2022]
|
60
|
Qin X, Zhang H, Ye D, Yao X, Zhang S, Dai B. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication. Andrology 2013; 1:512-6. [PMID: 23536478 DOI: 10.1111/j.2047-2927.2013.00078.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 01/08/2013] [Accepted: 01/29/2013] [Indexed: 11/30/2022]
Abstract
Testosterone is the major precursor of estradiol (E2) in men. We hypothesized that, in metastatic prostate cancer, androgen deprivation therapy suppression of serum androgen to the castration level may also disrupt serum E2 level, and variation in serum E2 level might play a role in the development of castration-resistant prostate cancer. Our investigation was designed to observe the variation in circulating oestrogen and androgen levels in metastatic prostate cancer patients after combined androgen blockade, and to explore the possible clinical significance. We recruited 105 consecutive metastatic prostate cancer patients who were treated with combined androgen blockade from June to August 2011, and divided them into three groups according to different hormone-sensitivity status, including 58 hormone-sensitive prostate cancers, 27 after failure of first-line hormone therapy (androgen-independent prostate cancer) and 20 castration-resistant prostate cancers. Another 36 consecutive patients with treatment-naive metastatic prostate cancer during the same period were used as controls. Serum testosterone, E2 and E2/testosterone (E2/T) ratio were analysed and compared between the groups. After combined androgen blockade, testosterone was suppressed to a low level, regardless of different hormone sensitivity (p > 0.05). Mean serum testosterone was 4.07, 0.15, 0.11 and 0.09 ng/mL in treatment-naive, hormone-sensitive, androgen-independent and castration-resistant prostate cancer respectively. For each group, mean E2 was 33.06, 9.23, 9.13 and 15.05 pg/mL respectively. Mean E2/T was 9.58, 269.29, 292.06 and 996.67 respectively. Recovery of E2 and increased E2/T ratio were more significantly associated with combined androgen blockade failure, especially in castration-resistant prostate cancer (p < 0.001). This study indicated that metabolism of oestrogen might change during combined androgen blockade in metastatic prostate cancer patients, and oestrogen-related pathways might play a role in the development of castration-resistant prostate cancer.
Collapse
|
61
|
Bi B, Xiao X, Zhang H, Gao J, Tao M, Niu H, Wang Y, Wang Q, Chen C, Sun N, Li K, Fu J, Gan Z, Sang W, Zhang G, Yang L, Tian T, Li Q, Yang Q, Sun L, Li Y, Rong H, Guan C, Zhao X, Ye D, Zhang Y, Ma Z, Li H, He K, Chen J, Cai Y, Zhou C, Luo Y, Wang S, Gao S, Liu J, Guo L, Guan J, Kang Z, Di D, Li Y, Shi S, Li Y, Chen Y, Flint J, Kendler K, Liu Y. A comparison of the clinical characteristics of women with recurrent major depression with and without suicidal symptomatology. Psychol Med 2012; 42:2591-2598. [PMID: 22716960 PMCID: PMC3488812 DOI: 10.1017/s003329171200058x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2011] [Revised: 03/02/2012] [Accepted: 03/06/2012] [Indexed: 11/22/2022]
Abstract
BACKGROUND The relationship between recurrent major depression (MD) in women and suicidality is complex. We investigated the extent to which patients who suffered with various forms of suicidal symptomatology can be distinguished from those subjects without such symptoms. METHOD We examined the clinical features of the worst episode in 1970 Han Chinese women with recurrent DSM-IV MD between the ages of 30 and 60 years from across China. Student's t tests, and logistic and multiple logistic regression models were used to determine the association between suicidality and other clinical features of MD. RESULTS Suicidal symptomatology is significantly associated with a more severe form of MD, as indexed by both the number of episodes and number of MD symptoms. Patients reporting suicidal thoughts, plans or attempts experienced a significantly greater number of stressful life events. The depressive symptom most strongly associated with lifetime suicide attempt was feelings of worthlessness (odds ratio 4.25, 95% confidence interval 2.9-6.3). Excessive guilt, diminished concentration and impaired decision-making were also significantly associated with a suicide attempt. CONCLUSIONS This study contributes to the existing literature on risk factors for suicidal symptomatology in depressed women. Identifying specific depressive symptoms and co-morbid psychiatric disorders may help improve the clinical assessment of suicide risk in depressed patients. These findings could be helpful in identifying those who need more intense treatment strategies in order to prevent suicide.
Collapse
|
62
|
Qin S, Jin J, Guo J, Wang J, Zhou F, Huang Y, Ren X, Ye D, Wang Q, Pan S. A Phase IV Multicenter Study of the Efficacy and Safety of Sunitinib as First-Line Therapy in Chinese Patients with Metastatic Renal Cell Carcinoma (MRCC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33423-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
63
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2012; 32:663-9. [PMID: 22391558 DOI: 10.1038/onc.2012.67] [Citation(s) in RCA: 441] [Impact Index Per Article: 36.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The TET (ten-eleven translocation) family of α-ketoglutarate (α-KG)-dependent dioxygenases catalyzes the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine and 5-carboxylcytosine, leading to eventual DNA demethylation. The TET2 gene is a bona fide tumor suppressor frequently mutated in leukemia, and TET enzyme activity is inhibited in IDH1/2-mutated tumors by the oncometabolite 2-hydroxyglutarate, an antagonist of α-KG, linking 5mC oxidation to cancer development. We report here that the levels of 5hmC are dramatically reduced in human breast, liver, lung, pancreatic and prostate cancers when compared with the matched surrounding normal tissues. Associated with the 5hmC decrease is the substantial reduction of the expression of all three TET genes, revealing a possible mechanism for the reduced 5hmC in cancer cells. The decrease of 5hmC was also observed during tumor development in different genetically engineered mouse models. Together, our results identify 5hmC as a biomarker whose decrease is broadly and tightly associated with tumor development.
Collapse
|
64
|
Zou D, Han W, You S, Ye D, Wang L, Wang S, Zhao J, Zhang W, Jiang X, Zhang X, Huang Y. In vitro study of enhanced osteogenesis induced by HIF-1α-transduced bone marrow stem cells. Cell Prolif 2011; 44:234-43. [PMID: 21535264 DOI: 10.1111/j.1365-2184.2011.00747.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVES Hypoxia-inducible factor 1α (HIF-1α) is a pivotal regulator of hypoxic and ischaemic vascular responses that drives transcriptional activation of hundreds of genes involved in vascular reactivity, angiogenesis and arteriogenesis. Previous reports based on gene knockout technology have demonstrated that HIF-1α can promote osteogenesis. However, this protein is easily degraded in a normoxic state, which makes in vitro studies of HIF-1α-induced mesenchymal stem cell (MSC) osteogenesis difficult. For better understanding of HIF-1α promoting osteogenesis, the role of HIF-1α-induced MSC osteogenesis in the normoxic state has been investigated here. MATERIALS AND METHODS HIF-1α was made to overexpress using a lentiviral vector, and its effects on bone marrow-derived mesenchymal stem cell (BMSC) osteogenesis were investigated. Real-time quantitative and western blotting (to assess expression levels of angiogenic and osteogenic related genes regulated by Lenti-HIF-1α), alkaline phosphatase (ALP) and alizarin red-S staining analyses, were performed. RESULTS In HIF-1α gene-transfected BMSCs, expression levels of angiogenic, cartilaginous and osteogenic genes were all increased significantly compared to Lenti LacZ-transfected cells, at both mRNA and protein levels. ALP activity and alizarin red-S staining were significantly enhanced in HIF-1α transduced cells compared to control cells, on day 21. CONCLUSIONS These results indicate that Lenti-HIF-1α can induce BMSC overexpression levels of angiogenic and osteogenic genes in vitro in the normoxic state. Further study will be focused on whether HIF-1α can also improve bone repair in vivo.
Collapse
|
65
|
Ou Y, Michaelson MD, Sengeløv L, Saad F, Houede N, Ostler PJ, Stenzl A, Daugaard G, Jones RJ, Laestadius F, Bahl A, Castellano DE, Gschwend J, Maurina T, Ye D, Chen I, Wang S, Maneval EC, Oudard S. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4515] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
66
|
Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets 2011; 10:782-96. [PMID: 20578983 DOI: 10.2174/156800910793605857] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2010] [Accepted: 05/18/2010] [Indexed: 11/22/2022]
Abstract
Tumors are invariably less well-oxygenated than the normal tissues from which they arose. Hypoxia-inducible factor-1 (HIF-1), a key transcriptional regulator, plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The expression, activity and stability of HIF-1 is not only induced in response to reduced oxygen availability but also modulated through PI-3K, MAPK, autocrine signaling pathways, E3 ubiquitin ligases, and other regulators. The regulators and effects of HIF-1 in cancer have intensively provided us a new clue for the HIF-1 targeting anticancer therapy. This review evaluates the HIF-1 structure, the regulation mechanisms, the functions in cancer and corresponding anticancer strategies.
Collapse
|
67
|
Shen Z, Ren Y, Ye D, Guo J, Kang C, Ding H. Significance and relationship between DJ-1 gene and surviving gene expression in laryngeal carcinoma. Eur J Histochem 2011; 55:e9. [PMID: 21556124 PMCID: PMC3167345 DOI: 10.4081/ejh.2011.e9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2010] [Revised: 02/08/2011] [Accepted: 02/22/2011] [Indexed: 01/09/2023] Open
Abstract
This study aimed at exploring the correlation between DJ-1 gene and survivin gene in laryngeal squamous cell carcinoma by analyzing their gene expression levels and their relationship with clinicopathologic parameters. The expression of DJ-1 gene and survivin gene in 82 laryngeal carcinoma tissues from patients and 82 negative surgical margin tissue samples were detected by immunohistochemistry, respectively. The correlation of their expression levels and patients' clinical parameters were then analyzed by Pearson correlation analysis. The positive detection rates of DJ-1 and survivin in laryngeal carcinoma tissues were 71.95% and 60.98%, which were higher than those of the normal control that were 29.27% and 0.00%, respectively (P<0.01). The positive detection rates of DJ-1 and survivin were found associated with tumor stages (P<0.05), but not with lymph node metastasis. The DJ-1 gene expression level was related to cell differentiation (P<0.05). Finally, a positive correlation between DJ-1 and survivin gene expression in laryngeal carcinoma was found. The overall survival rate of patients was 51.2%, and disease-free survival (DFS) was 39.0%. DFS in DJ-1 negative-expression group was 87.0%, and 20.3% in DJ-1 positive-expression group. The negative expression of DJ-1 was associated with a shorter mean patient DFS time (44.643±1.417 months), whereas positive expression of DJ-1 was associated with a longer mean DSF time (25.943±;1.297 months). DJ-1 and survivin play a vital role in the occurrence and development of laryngeal carcinoma. DJ-1 may promote the carcinogenesis of laryngeal cells by up-regulating the survivin gene expression.
Collapse
|
68
|
|
69
|
Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai O, Liu W, Xie X, Wang Z, Fang J, Chen Y. RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene 2010; 29:5404-15. [PMID: 20603618 DOI: 10.1038/onc.2010.270] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Vascular endothelial growth factors (VEGFs) are crucial regulators of angiogenesis and vasculogenesis. The autocrine VEGF signaling is required for maintaining the homeostasis of vasculature. Dysregulation of angiogenesis is implicated in the development of many human cancers, especially in clear-cell renal cell carcinoma (ccRCC), a highly vascularized tumor. Meanwhile, antiangiogenesis has become a mainstay in the treatment of human cancers. In this study, we analyzed the functional roles of RKTG (Raf Kinase Trapping to Golgi), a negative regulator of mitogen-activated protein kinase (Raf/MEK/ERK) signaling, by sequestration of Raf kinase to the Golgi apparatus, in angiogenesis and ccRCC. Through a series of in vitro and in vivo experiments, we found that RKTG has a negative effect on cell proliferation, migration, sprouting and angiogenesis of endothelial cells. RKTG, by suppressing mitogen-activated protein kinase signaling, negatively regulates the transactivation activity of hypoxia-inducible factor 1α (HIF-1α) by inhibiting formation of HIF-1α/p300 complex and suppressing VEGF transcription, thereby reducing hypoxia-induced VEGF production. The expression level of RKTG is significantly downregulated in clinical ccRCC tumor samples, with an inverse correlation with VEGF expression level. These results highlight the functional roles of RKTG and its regulated Raf/ERK/MEK signaling cascade in angiogenesis and autocrine VEGF signaling. In addition, this study indicates that RKTG is likely implicated in the development of ccRCC through its regulation on angiogenesis.
Collapse
|
70
|
Xu B, Shen L, Ye D, Jappe A, Wang H, Yuan R, Wu Y. Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Shen Y, Ye D, Yao X, Zhang S, Dai B, Zhang H, Zhu Y, Zhu Y, Shi G, Ma C, Xiao W. UP-2.126: Low Dose Metronomic Oral Combined Administration of Etoposide and Cyclophosphamide in Metastatic Hormone Refractory Prostate Cancer After Docetaxol or Mitoxantrone Chemotherapy: A Phase II Study in China. Urology 2009. [DOI: 10.1016/j.urology.2009.07.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
72
|
Tang X, Pan F, Xia G, Liao F, Ge R, Mei Y, Ye D, Xu S, Xu J. A single-nucleotide polymorphism marker within theFCRL5gene andHLA-B27positive Han Chinese ankylosing spondylitis patients. ACTA ACUST UNITED AC 2009; 74:314-6. [DOI: 10.1111/j.1399-0039.2009.01335.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
73
|
Qin X, Ma C, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Ye D. UP-2.125: Palliative Transurethral Resection of the Prostate (TURP) May Improve Cancer Control in Hormone Sensitive Metastatic Prostate Cancer (PCa). Urology 2009. [DOI: 10.1016/j.urology.2009.07.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
74
|
Hoekstra M, Ye D, Hildebrand R, van Berkel T, van Eck M. Abstract: S3-17 ADRENAL SR-BI IS A NOVEL THERAPEUTIC TARGET IN STRESSINDUCED CARDIOVASCULAR DISEASE. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71482-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Ye D, Hildebrand R, Berbee J, de Haan W, Hoekstra M, van Berkel T, Rensen P, van Eck M. Abstract: 1455 CHOLESTERYL ESTER TRANSFER PROTEIN MODULATES LPSINDUCED TNF-A PRODUCTION AND FORMS A HOST DEFENSE MECHANISM AGAINST SYSTEMIC INFLAMMATION. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)70100-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|